New hope for Tough-to-Treat lymphoma when standard drugs fail
NCT ID NCT07264894
Summary
This study is testing a new combination of four targeted drugs for adults with mantle cell lymphoma, a type of blood cancer, that has come back or stopped responding to a common type of medication called a BTK inhibitor. The goal is to see if this new drug mix can better control the cancer and help patients live longer. The treatment involves an initial 6-cycle phase followed by a longer-term maintenance phase to try to prevent the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.